Nasus Pharma Ltd. appointed Eyal Rubin as Executive Vice President and Chief Financial Officer. Mr. Rubin brings over 20 years of financial leadership experience in the biotechnology and pharmaceutical industries. He will oversee financial operations as Nasus Pharma advances its pipeline of intranasal therapeutics. The Company believes Mr. Rubin’s expertise will support its growth. Nasus Pharma is developing intranasal powder products for acute medical conditions, with a focus on needle-free alternatives. The proprietary powder-based intranasal technology aims for rapid and reliable drug delivery. For more information, visit www.nasuspharma.com.

Read more at GlobeNewswire: Nasus Pharma Strengthens Leadership Team, Appointing Eyal